Friday, May 06, 2016 12:19:58 PM
"A second baby with aggressive leukaemia has been treated in London with "designer immune cells" developed by Cellectis and, six months after treatment, remains in remission, the French biotech firm said.
Cellectis shares jumped 14 percent following Friday's news.
The first human use of the company's cell therapy made headlines worldwide in November when one-year-old Layla was cleared of previously incurable leukaemia at Britain's Great Ormond Street Hospital (GOSH).
Details of the latest compassionate care case, also treated at GOSH, were presented at the American Society of Gene & Cell Therapy annual meeting in Washington.
The so-called UCART19 injection works by adding new genes to healthy donated immune cells known as T-cells, which arm them against leukaemia.[more]
Recent CLLS News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 10:00:09 AM
- Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca • GlobeNewswire Inc. • 05/06/2024 06:00:00 AM
- Cellectis Appoints Arthur Stril as Interim Chief Financial Officer • GlobeNewswire Inc. • 05/02/2024 08:30:00 PM
- Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 04/29/2024 08:46:43 PM
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs • GlobeNewswire Inc. • 04/10/2024 08:30:00 PM
- Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting • GlobeNewswire Inc. • 04/08/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 09:45:04 PM
- Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) • GlobeNewswire Inc. • 01/16/2024 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 09:35:09 PM
- Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 • GlobeNewswire Inc. • 12/22/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 09:01:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/05/2023 09:01:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/17/2023 09:56:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/17/2023 09:35:04 PM
- Cellectis’ Shareholders Meeting to be Held on December 22, 2023 • GlobeNewswire Inc. • 11/17/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/15/2023 12:48:55 PM
- Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca • GlobeNewswire Inc. • 11/15/2023 07:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 09:01:32 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 09:35:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 09:30:06 PM
- Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 • GlobeNewswire Inc. • 11/06/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/02/2023 08:35:12 PM
- Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting • GlobeNewswire Inc. • 11/02/2023 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/01/2023 08:35:05 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM